[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-fibrillation-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-fibrillation-recurrent":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,78,101,127,151,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639560","pulsed-field-ablation-outcomes-with-efficacy-and-randomization-in-atrial-fibrillation-power-af-100639560",false,"NCT07601763","Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)","Pulsed Field Ablation for Atrial Fibrillation Including Posterior Wall and Linear Ablation: A Randomized Controlled Trial of Safety and Efficacy (POWER-AF)","POWER-AF","Inclusion Criteria:\n\n1. Atrial fibrillation patients who will accept catheter ablation.\n2. Age ≥ 18.\n3. Be capable of understanding and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Have contraindications for catheter ablation (such as atrial thrombosis, decompensated heart failure, etc.)\n2. Have accepted catheter ablation before.\n3. Myocardial infarction, or any cardiac interventional\u002Fsurgery has been performed within 3 months.\n4. Had a stroke or transient ischemic attack within 6 months.\n5. Allergy to iodine contrast agents.\n6. Participate in clinical trials related to other drugs or devices.\n7. Pregnant women, lactating women, or women with plans to become pregnant shortly.\n8. Active stage of infection.\n9. Secondary atrial fibrillation, such as combined with rheumatic heart disease, hypertrophic cardiomyopathy, etc.\n10. Patients who do not agree to be enrolled or are unable to cooperate to complete the study","ALL","18 Years",{"count":20,"type":21},1574,"ESTIMATED","INTERVENTIONAL",[24],"NA","Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice. As of 2019, there were approximately 59.7 million patients with AF worldwide, including atrial flutter (AF). Atrial fibrillation can significantly increase the risks of stroke, thromboembolism and heart failure in patients, seriously affecting their quality of life.\n\nCatheter ablation is the main means for rhythm control in patients with atrial fibrillation. A large number of clinical studies have confirmed the effectiveness and safety of catheter ablation for atrial fibrillation. It is significantly superior to drug treatment in maintaining sinus rhythm and can significantly improve symptoms and quality of life.\n\nPulsed electric field ablation (PFA) is a novel ablation method that utilizes pulsed electric fields as energy. It uses multiple short-duration and high-voltage electrical pulses to release ablation energy, selectively causing myocardial cells to rupture and die. However, it has no obvious damaging effect on blood vessels, nerves, and tissues around the heart, such as the lungs, esophagus, and phrenic nerve.\n\nThis trial was designed based on the advantage of the characteristic that PFA does not damage the esophagus, confining the damage to the posterior half of the left atrium and the circumferential isthmus of the mitral valve. While improving the ablation success rate, it is possible to protect the function of the left atrium. This study aims to verify the superiority of the new rhythm control strategy in a large-scale population by launching a prospective randomized controlled trial.",[27,28,29,30,31],"Atrial Fibrillation (AF)","Atrial Fibrillation Ablation","Atrial Fibrillation Recurrent","Pulsed Field Ablation","Radiofrequency Catheter Ablation","RECRUITING","2026-05-24",{"date":35,"type":36},"2026-05-28","ACTUAL",{"date":38,"type":36},"2025-04-16",{"date":40,"type":21},"2028-11-30",{"name":42,"class":43},"China National Center for Cardiovascular Diseases","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":44},"100535528","radiofrequency-and-cryoablation-of-the-posterior-wall-of-the-left-atrium-100535528","NCT06253000","Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium","Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation","Inclusion Criteria:\n\n* Age over 18 years old;\n* Atrial fibrillation resistant to antiarrhythmic therapy;\n* Persistent and long-persisting form of atrial fibrillation;\n* The patient's consent to participate in the study.\n\nExclusion Criteria:\n\n* Age under 18 and over 80 years old;\n* The presence of another cardiac pathology requiring surgical treatment;\n* Congenital heart defects;\n* Previous \"open\" cardiac surgery;\n* Bone marrow diseases;\n* Pathology of the blood coagulation system;\n* The left ventricular ejection fraction is less than 40%;\n* Moderate to severe renal insufficiency (creatinine clearance \\\u003C50 ml\u002Fmin);\n* Drug-resistant hypertension (despite hypotensive therapy);\n* Organically altered mitral valve;\n* There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons;\n* The patient's participation in another clinical trial.","80 Years",{"count":54,"type":21},158,[24],"Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times.\n\nThe main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and\u002For cryoenergy to eliminate destructive damage to the left atrium (LA).\n\nThe aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.",[58,59,60,61,29],"Stroke","Acute Cerebrovascular Accident","Transient Ischemic Attack","Death",[63,64,65,66,67,68],"atrial fibrillation","radiofrequency ablation","cryoablation","left atrium","the posterior wall of the left atrium","atrial remodeling","2026-05-07",{"date":71,"type":36},"2026-05-08",{"date":73,"type":36},"2023-06-10",{"date":75,"type":21},"2026-12-30",{"name":77,"class":43},"Bakulev Scientific Center of Cardiovascular Surgery",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":44},"100459709","atrial-fibrillation-patients-treated-with-catheter-ablation-100459709","NCT05266144","Atrial Fibrillation Patients Treated With Catheter Ablation","A Prospective Cohort Study of Atrial Fibrillation Patients Treated With Catheter Ablation","Inclusion Criteria:\n\n* Non-valvular atrial fibrillation, including paroxysmal atrial fibrillation and persistent atrial fibrillation\n* 18-80 years old\n* The anteroposterior diameter of the left atrium is less than 50mm via TTE\n* Patient meets the intervention criteria for bilateral pulmonary vein isolation after evaluation by electrophysiological specialists\n* Patient consents to ablation treatment\n\nExclusion Criteria:\n\n* Intra-atrial thrombus detected by TEE\n* Hyperthyroidism\n* Previous radiofrequency ablation for atrial fibrillation",{"count":86,"type":21},300,"OBSERVATIONAL","This is a single-center prospective observational cohort study of atrial fibrillation patients treated with radiofrequency ablation.",[90,29],"Atrial Fibrillation","2025-06-04",{"date":93,"type":36},"2025-06-05",{"date":95,"type":36},"2020-09-04",{"date":97,"type":21},"2025-12-31",{"name":99,"class":100},"Peking Union Medical College Hospital","OTHER",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":44},"100531390","pulsed-field-ablation-versus-conventional-radiofrequency-catheter-ablation-for-repeat-pvi-in-patients-with-paroxysmal-af-100531390","NCT06199180","Pulsed Field Ablation Versus Conventional Radiofrequency Catheter Ablation for Repeat PVI in Patients With Paroxysmal AF","Pulsed Field Ablation Versus Conventional Radiofrequency Catheter Ablation for Repeat","REPEAT-AF","Subjects who meet all of the following inclusion criteria at screening will be eligible for enrolment:\n\n* Patient had 1 previous PVI with either cryoballoon, RF ablation or PFA\n* Index PVI occurred within \\\u003C5 years prior to enrolment\n* Documented AF recurrence \\>30 seconds\n* Symptomatic AF\n* Paroxysmal AF\n* Age \\>18 and \\\u003C80 years\n* Willing and capable to provide informed consent\n* Able and willing to participate in all examinations and follow-up visits and tests associated with this clinical study\n\nSubjects who meet ANY of the following exclusion criteria will be excluded from the study:\n\n* Persistent AF (by diagnosis of duration \\>7 days)\n* Concomitant\u002F prior diagnosis for atrial tachycardia (AT) and\u002For atrial flutter (AFl). Note typical cavotricuspid isthmus dependent flutter is not an exclusion criterium.\n* Underwent additional ablations outside the pulmonary veins during index AF ablation\n* AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse, or other reversible\u002Fnon-cardiac causes\n* Contraindication to, or unwillingness to use, systematic anticoagulation\n* Left ventricular ejection fraction (LVEF) \\\u003C30% as documented by transthoracic echo (TTE) (within \\\u003C3 months prior)\n* Left atrial volume index \\>60 ml\u002Fm2\n* Clinically significant arrhythmias other than AF\n* Previous surgery for AF\n* New York Heart Association (NYHA) Functional Class III or IV\n* Presence of intramural thrombus, tumour or other abnormality that precludes safe catheter introduction or manipulation\n* BMI \\>35 kg\u002Fm2\n* Significant or symptomatic hypotension, bradycardia, or chronotropic incompetence\n* Chronic renal insufficiency of \\\u003C15 mL\u002Fmin\u002F1.73 m2 or any history of renal dialysis, or history of renal transplant\n* Hemodynamically significant valvular disease\n* Presence of patent foramen ovale (PFO) or atrial septal defect (ASD) closure device\n* History of abnormal bleeding and\u002For clotting disorder\n* History of rheumatic fever\n* Severe lung disease, pulmonary hypertension, or any lung disease. Only if involving abnormal blood gases or significant dyspnoea\n* Clinically significant systemic infection or sepsis\n* Life expectancy \\\u003C1 year\n* Sensitivity to contrast media not controlled by pre-medication\n* Any of the following within the 3 months prior to enrolment:\n\n  * Myocardial infarction\n  * Unstable angina\n  * Percutaneous coronary intervention\n  * Heart failure hospitalization\n  * Stroke or TIA\n  * Significant bleeding\n  * Pericarditis\u002Feffusions\n  * Left atrial thrombus\n* Coronary artery bypass grafting\u002Fatriotomy within 6 months prior\n* Organ or haematologic transplant, or currently being evaluated for an organ transplant\n* Women who are pregnant or breastfeeding",{"count":110,"type":21},154,[24],"Various methods exist for performing pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF), including thermal ablation and pulse-field ablation (PFA). However, in cases requiring a second PVI for recurrent AF, radiofrequency ablation (RFA) is utilized in nearly 95% of instances post-acquiring a 3D high-density map from the left atrium (LA). Up to 85% of patients experiencing recurrent AF after the initial PVI exhibit pulmonary vein (PV) reconnections, often identified as the cause of AF.\n\nPFA has demonstrated its safety and efficiency compared to RFA as a swift technique for performing ablation. Yet, whether PFA or RFA stands out as superior or safer when applied for a second PVI remains unclear, as no randomized controlled trial has investigated this comparison. The proposed REPEAT-AF trial aims to randomize 154 AF patients experiencing recurrent AF after the initial PVI, assigning them in a 1:1 ratio to either RFA or PFA. Each patient will receive an implantable cardiac monitor to precisely detect any AF recurrences.",[29],[115,116,64,117],"pulmonary vein isolation","pulsed field ablation","implantable cardiac monitor","2024-12-09",{"date":120,"type":36},"2024-12-10",{"date":122,"type":36},"2024-09-20",{"date":124,"type":21},"2028-09",{"name":126,"class":100},"University Medical Center Groningen",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100569466","a-study-on-the-relationship-between-individualized-low-voltage-regions-in-left-atrium-and-the-mechanism-of-atrial-fibrillation-in-persistent-atrial-fibrillation-under-ultra-high-resolution-mapping-100569466","NCT06694610","A Study on the Relationship Between Individualized Low Voltage Regions in Left Atrium and the Mechanism of Atrial Fibrillation in Persistent Atrial Fibrillation Under Ultra-High-Resolution Mapping","ILVRA-PAFM-UAH","Inclusion Criteria:\n\n1. Patients aged 18 to 85 years;\n2. Diagnosed with drug-refractory, symptomatic, persistent atrial fibrillation; Definition: At least one electrocardiogram (ECG) record of an atrial fibrillation episode within 12 months prior to enrollment.\n3. Non-valvular atrial fibrillation;\n4. Able to understand the purpose of the study, voluntarily participate in the study, the patient or their legal representative signs the informed consent form, and willing to complete follow-ups as required by the study protocol.-\n\nExclusion Criteria:\n\n1. Atrial fibrillation secondary to thyroid disease or other reversible factors;\n2. Imaging studies indicating intracardiac thrombus;\n3. Moderate to severe mitral stenosis or regurgitation;\n4. Left ventricular ejection fraction \\\u003C40%, or New York Heart Association (NYHA) functional class III or IV;\n5. Unstable angina;\n6. Myocardial infarction (MI) or coronary artery bypass grafting (CABG) within 3 months prior to enrollment;\n7. Presence of mural thrombus, space-occupying disease, or other abnormalities that hinder vascular puncture or catheter manipulation;\n8. Contraindications to anticoagulation and a history of blood coagulation or bleeding abnormalities;\n9. Patients with active systemic infections; Patients who have had an atrial septal closure device implanted within the last 6 weeks;\n10. Female patients who are pregnant, breastfeeding, or unable to use contraception during the study period;\n11. Patients with a life expectancy of less than 12 months (e.g., advanced malignant tumors); patients who have had an atrial septal closure device implanted within the last 6 weeks;\n12. Conditions affecting vascular access;\n13. Patients who are concurrently participating in other drug or device clinical trials;\n14. Any other abnormalities or diseases that the investigator deems should exclude the patient from the study enrollment.","85 Years",{"count":136,"type":21},120,[24],"The latest OCTARAY multi-electrode mapping catheter and TUREref technology were used to perform ultra-high precision mapping on the left atrial and left atrial auricle of persistent atrial fibrillation in the condition of sinus rhythm and atrial fibrillation respectively, and the density and accuracy of potential were significantly improved. According to the mapping results, the numerical calculation of the personalized low voltage region was carried out, and the personalized ablation route was designed according to the low voltage region.",[29],[141],"心房颤动（Atrial Fibrillation）","NOT_YET_RECRUITING","2024-11-15",{"date":145,"type":36},"2024-11-19",{"date":143,"type":21},{"date":148,"type":21},"2026-04-05",{"name":150,"class":100},"The Third People's Hospital of Chengdu",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100531810","phase-3-spironolactone-for-the-maintenance-of-sinus-rhythm-in-patients-with-atrial-fibrillation-100531810","NCT06204640","SPironolactONe for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation","SPironolactONe for the Maintenance of Sinus Rhythm in Hypertensive Patients With Atrial Fibrillation and Preserved Left Ventricular Ejection Fraction (SPONSoR Study).","SPONSoR","Inclusion Criteria:\n\n* Male or female (since spironolactone is not recommended during pregnancy and breastfeeding, a highly sensitive pregnancy test (serum HCG) will be systematically carried out in women of childbearing age and information will be given to non-pregnant women at the time of inclusion to instruct them to use an effective method of contraception during all the study period. Effective methods include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal, or progestogen-only hormonal contraception associated with inhibition of ovulation : oral, injectable, implantable, or intrauterine device, or intrauterine hormone-releasing system, or bilateral tubal occlusion or vasectomised partner, or sexual abstinence)\n* Age \\> 18 years\n* Hypertension defined as current use of anti-hypertensive drugs for more than 12 months\n* Paroxysmal or no long-standing persistent AF (as defined by the ESC guidelines) with at least 1 episode within the preceding 6 months\n* Sinus rhythm at enrolment\n* Patient signed consent\n* Willing to comply with scheduled visits, as outlined in the protocol\n* French speaking\n* Recipients of the social security regime\n\nExclusion Criteria:\n\n* Contraindications to spironolactone therapy: pregnancy, breastfeeding, intolerance, hyperkalemia (\\>5.0 mmol\u002FL), severe renal dysfunction (defined as an estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1,73m² (per the CKD-EPI equation). Subjects with serum creatinine ≥2.5 mg\u002Fdl are also excluded even if their eGFR is ≥30 ml\u002Fmin\u002F1,73m²), Severe liver dysfunction.\n* Patients already treated by other potassium sparing medication (amiloride, triamterene) or MRA (spironolactone, eplerenone, potassium canreonate, finerenone).\n* Other MRAs indication: aldosteronism, heart failure, cirrhosis ascites, nephrotic syndrome, myasthenia\n* LVEF \\\u003C 40% obtained within 6 months prior to V0\n* Planned atrial fibrillation ablation within 6 months after randomization\n* Moderate-to-severe valvular heart disease\n* Permanent AF or long-standing persistent AF as defined by the ESC guidelines\n* AF on the ECG at the inclusion visit\n* Previous left atrial ablation or previous maze or maze-like surgery\n* Acute, reversible or secondary AF (infection, hyperthyroidism, pericarditis or myocarditis)\n* Left atrium diameter \\> 60 mm obtained within 6 months prior to V0\n* Contraindication to oral anticoagulation therapy\n* Patients with persistent bradycardia of less than 50 beats per minute, a PR interval of 0.2 second or more on ECG, second degree (or higher) atrioventricular block, and snus-node disease without an implanted pacemaker\n* Hemodynamic instability and unstable conditions: angina or acute coronary syndrome or heart failure during the last 3 months, cardiogenic shock\n* A life expectancy of 1 years or less\n* Patients included or planning to be included in another medical research protocol whose pharmacological and scientific rationales might interfere with the Sponsor trial\n* Patients unable to complete the protocol follow-up\n* Pregnant or nursing women\n* Adults with protective measures (curatorship or tutorship) and vulnerable patients",{"count":160,"type":21},580,[162],"PHASE3","Introduction:\n\nThere is evidence that aldosterone and the activation of its receptor, mineralocorticoid receptor (MR), promote cardiac fibrosis and electrical disturbances. clinical data suggest that MRAs could have positive effects on AF burden, but some inconsistent results have been reported.\n\nTherefore, investigators propose to perform a randomized, multicenter, open blinded end-point (PROBE) study to evaluate the efficacy of spironolactone on AF recurrence in hypertensive patients with preserved LVEF.\n\nMaterials and methods:\n\nSPONSoR trial will be a multicenter, landmark, randomized, open blinded end-point (PROBE) trial of the MRA, spironolactone, in 580 hypertensive patients referred for AF with preserved LVEF.\n\n580 patients will be randomized in a 1:1 ratio to either receive oral spironolactone once daily on top of standard therapy or standard therapy alone, started the day of randomization and continued for 12 months. Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit. AF detection will be provided by the use of a wearable optical photoplethysmography (PPG) device (ScanWatch 42mm®, Withings) throughout the duration of the study. These wearables optical PPG devices (ScanWatch 42mm®, Withings).\n\nThe trial duration is 3 years (24 months for inclusion with 12 months of follow-up; total duration participation for the patient of 12 months).",[29],"2024-01-03",{"date":167,"type":36},"2024-01-12",{"date":169,"type":21},"2024-03-01",{"date":171,"type":21},"2029-01-01",{"name":173,"class":100},"University Hospital, Caen",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":4},"100523691","a-prospective-study-of-repeat-ablation-in-patients-with-recurrent-persistent-atrial-fibrillation-pulmonary-vein-isolation-vs-adjunct-posterior-wall-isolation-repair-pers-af-study-100523691","NCT06098989","A Prospective Study of REPeat Ablation In Patients With Recurrent PERSistent Atrial Fibrillation: Pulmonary Vein Isolation vs. Adjunct Posterior Wall Isolation (REPAIR PERS-AF Study)","REPAIR PERS-AF","Inclusion Criteria:\n\n* Symptomatic patients with persistent AF and indication for repeat ablation\n* procedure.\n* Patients with recurrent persistent AF (with a duration \\\u003C3 year, at least one episode longer than 7 days during the last 6 months and have been electrically cardioverted at least once during the last 12 months) after previous catheter ablation.\n* Patients with up to two previous catheter ablations for AF are included if the procedures only involved PVI. Previous PVI procedure(s) with both cryoablation and radiofrequency ablation are accepted.\n* Patients have taken at least one antiarrhythmic drug.\n* Patients are willing to participate in the study and sign the patient information form.\n* Age: 18-80 years old.\n* Patients must be on continuous anticoagulation with warfarin (INR 2-3) or direct oral anticoagulant for \\>4 weeks prior to the ablation.\n\nExclusion Criteria:\n\n* Patients with \\>2 ablation procedures in the LA for AF or atrial flutter\n* Previous ablation procedures for AF involving ablation strategies beyond PVI\n* Duration of persistent AF \\>3 years\n* Presence of atrial flutter or atrial tachycardia\n* Presence of an intracavitary thrombus\n* Uncontrolled heart failure\n* Severe valvular disease\n* LA diameter \\> 60 mm\n* Structural heart disease involving more than moderate valvular stenosis and\u002For\n* Insufficiencies\n* Rheumatic heart disease\n* Cardiac surgery for valvopathy or for congenital heart disease\n* Patients with contraindications to systemic anticoagulation\n* Severe renal dysfunction\n* Patients who are or may potentially be pregnant.\n* Patient not able to be followed up.",{"count":182,"type":21},150,[24],"This study aims to investigate the best strategy for repeat ablation of recurrent persistent atrial fibrillation (AF) after previous persistent AF ablation involving pulmonary vein isolation (PVI) along. Patients with low voltage areas on the posterer wall will be randomized to PVI alone or the posterer wall isoaltion (PWI) in addition to PVI.",[186,29],"Atrial Fibrillation, Persistent",[188,189,190,191],"Atrial fibrillation","Radiofrequency ablation","Posterior wall isolation","Pulmonary vein isolation","2023-10-22",{"date":194,"type":36},"2023-10-25",{"date":196,"type":21},"2023-11-15",{"date":198,"type":21},"2026-11-15",{"name":200,"class":100},"Haukeland University Hospital"]